Aachen, Germany – Grünenthal, a global leader in pain management and related diseases, announced on Monday 2 June, 2025, that it has agreed to acquire the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. This acquisition further strengthens Grünenthal’s footprint in Latin America and expands its portfolio in the region. As part of the agreement, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile.
The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions. Grünenthal will finance the acquisition using available liquidity and the financial terms of the transaction have not been disclosed.
Cialis® is a well-known medication indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men. This acquisition will expand Grünenthal’s Latin American Men’s Health product portfolio and is in line with the company’s strategy of targeted acquisitions.
Grünenthal’s CEO, Gabriel Baertschi, states, “Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal’s Latin American business. In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets.”
Since 2017, Grünenthal has invested over €2 billion in successful M&A transactions, significantly strengthening its profitability. This includes the acquisition of Nebido®, the European rights to Crestor® and Nexium®, as well as the global rights to Vimovo® (excluding the U.S. and Japan), Qutenza® and Zomig® (excluding Japan). In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik®.
Grünenthal, as a science-based, fully integrated pharmaceutical company, is dedicated to bringing innovative treatments and state-of-the-art technologies to patients worldwide. Their purpose is to change lives for the better, with a focus on working towards a World Free of Pain. The company’s headquarters are in Aachen, Germany, with affiliates in 28 countries across Europe, Latin America, and the U.S. Their products are available in approximately 100 countries, and in 2024, they employed around 4,300 people with revenues of €1.8 billion.
For further information on Grünenthal and their products, please visit their website at www.grunenthal.com. You can also follow them on LinkedIn, under Grunenthal Group, and Instagram at grunenthal.
For media inquiries and further information, please contact Maren Thurow, Head Global Communication, Grünenthal GmbH, 52099 Aachen, via email at Maren.Thurow@grunenthal.com or by phone at +44 7917 196855.
In Mexico, Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men.
Distributed by https://pressat.co.uk/
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.